Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

This article explores how eating junk food raises the risk of fatty liver diseases, examines symptoms, and highlights ...

Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications.

代谢功能障碍相关的脂肪性肝病（MASLD），影响着全球四分之一的人口，也是中国发病率最高的慢性肝病类型，目前我国有超过1.5亿患者。目前，生活方式干预仍然是MASLD治疗的主要手段，包括改变饮食和运动。热量限制（CR）已被证明是改善肝脏脂肪变性的有效 ...

Abdelmalek et al [120] documented that biopsy-proven NASH that has progressed to cirrhosis may no longer retain diagnostic histopathologic features of steatohepatitis in follow-up biopsy ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...

For NASH patients with moderate to advanced fibrosis, , who are 1 or 2 steps away from having cirrhosis, healthcare providers will want to be confident that their patient is going to take his or ...